The last mile in global poliomyelitis eradication

This article discusses the difficulties in the last phase of poliomyelitis eradication with uneven progress over the past five years. It outlines the three challenges that must be met if poliomyelitis is to be eradicated - a knowledge gap that must be confronted and addressed evaluation of the current strategies to deem satisfactory or non-satisfactory and community engagement and creation of grass-roots support for poliomyelitis eradication.

[1]  M. Pallansch,et al.  Fractional doses of inactivated poliovirus vaccine in Oman. , 2010, The New England journal of medicine.

[2]  M. Pallansch,et al.  Survey of poliovirus antibodies during the final stage of polio eradication in Egypt. , 2007, Vaccine.

[3]  Timothy D Baker,et al.  The impact of the national polio immunization campaign on levels and equity in immunization coverage: evidence from rural North India. , 2003, Social science & medicine.

[4]  N. Grassly,et al.  Asymptomatic wild-type poliovirus infection in India among children with previous oral poliovirus vaccination. , 2010, The Journal of infectious diseases.

[5]  J. Corander,et al.  Implications of a circulating vaccine-derived poliovirus in Nigeria. , 2010, The New England journal of medicine.

[6]  G. I. Div.  Wild poliovirus type 1 and type 3 importations - 15 countries, Africa, 2008-2009. , 2009 .

[7]  A. Sabin.  Perspectives on Current Use of Some Virus Vaccines in the USA: Measles, Rubella, Poliomyelitis, and Influenza in the USA: Contrasts in Control by Vaccination , 1979, Pediatric Research.

[8]  A. Malik,et al.  Antibody levels against polioviruses in children following Pulse Polio Immunization Program. , 2004, Indian pediatrics.

[9]  N. Grassly,et al.  Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India. , 2009, The Journal of infectious diseases.

[10]  M. Pate,et al.  Outbreak of Type 2 Vaccine-Derived Poliovirus in Nigeria: Emergence and Widespread Circulation in an Underimmunized Population , 2011, The Journal of infectious diseases.

[11]  D. Salk.  Eradication of poliomyelitis in the United States. II. Experience with killed poliovirus vaccine. , 1980, Reviews of infectious diseases.

[12]  R. Sutter,et al.  Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial , 2010, The Lancet.